Pharmazz Inc. to Present Positive Phase III Study Results of Centhaquine (PMZ-2010) at Military Health System Research Symposium
Pharmazz, Inc. will present data from its positive Phase III study on centhaquine (PMZ-2010), a resuscitative agent for hypovolemic shock patients, at the upcoming Military Health System Research Symposium in September 2022. The drug is already commercially available under the brand name Lyfaquin® in India and has shown safety and efficacy as an adjuvant to standard care.
Topics: biopharmaceutical hypovolemic shock treatment Phase III study